Elderly Clinical Trial
Official title:
Effects of β-glucan Based Dietary Fibres on Indomethacin-induced Hyperpermeability and Gut Microbiota Composition in Elderly: A Randomized Placebo-controlled Crossover Clinical Trial
NCT number | NCT05584254 |
Other study ID # | FODI |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | April 1, 2015 |
Est. completion date | August 14, 2017 |
Verified date | March 2023 |
Source | Örebro University, Sweden |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The investigators aim was to compare healthy young adults, senior orienteers (model of healthy ageing) and elderly with gastrointestinal symptoms on intestinal permeability, microbiota compositions and well-being. In addition, assess whether 3 weeks of oral intake of soluble or dispersible forms yeast-dervied beta-glucan could improve intestinal barrier function against drug-induced barrier disruption vs placebo for a cohort of elderly people with gastrointestinal symptoms, in a randomized double blinded placebo-controlled cross-over clinical trial.
Status | Completed |
Enrollment | 43 |
Est. completion date | August 14, 2017 |
Est. primary completion date | August 14, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 55 Years to 100 Years |
Eligibility | Elderly with gastrointestinal symptoms Inclusion Criteria: - Informed consent signed by study participant - Age >55 years - Scoring above 2 on the dimensions for diarrhoea and constipation on the Gastrointestinal symptoms rating scale (GSRS) - Mentally and physically fit to complete questionnaires during the study period Exclusion Criteria: - Known or genic gastrointestinal diseasewith strictures, malignance's and ischemia. - Inflammatory bowel diseases (IBD) - Participation in other clinical trials in the past three months. - Intake of medications know to change the inflammatory status (i.e proton pump inhibitors, antibiotic, anti-inflammtory medication (including NSAIDs) Healthy controls Inclusion Criteria: - Age = 18 years - Informed consent signed by the study participant - Mentally and physically fit to complete questionnaires during the study period Exclusion Criteria: - Previous abdominal surgery - A hypertonic condition demanding medical treatment - Diagnosed psychiatric disease - Lactose intolerance - Usage of medical prescribed medications, expect oral contraceptives, during the 14 days preceding study start - Premenstrual syndrome - Pregnant or breast feeding - Known or genic gastrointestinal disease, with strictures, malignance's and ischemia. - Inflammatory bowel diseases (IBD) - Participation in other clinical trials in the past three months. |
Country | Name | City | State |
---|---|---|---|
Sweden | Campus USÖ, Örebro University | Örebro |
Lead Sponsor | Collaborator |
---|---|
Örebro University, Sweden | Kerry Group |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Intestinal permeability at baseline (before indomethacin) | In vivo gastrointestinal permeability measured by oral intake of multi-sugar test before intake of indomethacin. Urine collected over 24 hours for measurement of excreted sugars. | Day 1 | |
Primary | Intestinal permeability at baseline (after indomethacin) | In vivo gastrointestinal (GI) permeability measured by oral intake of multi-sugar test after intake of indomethacin (GI barrier disruption challenge). Urine collected over 24 hours for measurement of excreted sugars. | Day 1 | |
Primary | Changes in Intestinal permeability 3 weeks after study supplementation 1 (before indomethacin). | Performed after study participants have orally taken study supplementation 1 for 3 weeks. In vivo gastrointestinal permeability measured by oral intake of multi-sugar test before intake of indomethacin. Urine collected over 24 hours for measurement of excreted sugars. | 3 weeks | |
Primary | Changes in intestinal permeability 3 weeks after study supplementation 1 (after indomethacin). | Performed after study participants have orally taken study supplementation 1 for 3 weeks.
In vivo gastrointestinal (GI) permeability measured by oral intake of multi-sugar test after intake of indomethacin (GI barrier disruption challenge). Urine collected over 24 hours for measurement of excreted sugars. |
3 weeks | |
Primary | Changes in intestinal permeability 3 weeks after study supplementation 2 (before indomethacin) | Performed after study participants have orally taken study supplementation 2 for 3 weeks.
In vivo gastrointestinal permeability measured by oral intake of multi-sugar test before intake of indomethacin. Urine collected over 24 hours for measurement of excreted sugars. |
3 weeks | |
Primary | Changes in intestinal permeability 3 weeks after study supplementation 2 (after indomethacin) | Performed after study participants have orally taken study supplementation 2 for 3 weeks.
In vivo gastrointestinal (GI) permeability measured by oral intake of multi-sugar test after intake of indomethacin (GI barrier disruption challenge). Urine collected over 24 hours for measurement of excreted sugars. |
3 weeks | |
Primary | Changes in intestinal permeability 3 weeks after study supplementation 3 (before indomethacin) | Performed after study participants have orally taken study supplementation 3 for 3 weeks.
In vivo gastrointestinal permeability measured by oral intake of multi-sugar test before intake of indomethacin. Urine collected over 24 hours for measurement of excreted sugars. |
3 weeks | |
Primary | Changes in intestinal permeability 3 weeks after study supplementation 3 (after indomethacin) | Performed after study participants have orally taken study supplementation 3 for 3 weeks.
In vivo gastrointestinal (GI) permeability measured by oral intake of multi-sugar test after intake of indomethacin (GI barrier disruption challenge). Urine collected over 24 hours for measurement of excreted sugars. |
3 weeks | |
Secondary | Microbiota diversity - at baseline | Faecal samples will be used for next-generation sequencing and analysed for diversity | Day 1 | |
Secondary | Bacterial species - at baseline | Faecal samples will be used for next-generation sequencing and analysed for bacterial species | Day 1 | |
Secondary | Changes in microbiota diversity 3 weeks after study supplementation 1 | Faecal samples will be used for next-generation sequencing and analysed for changes in microbiota diversity | 3 weeks | |
Secondary | Changes in bacterial species 3 weeks after study supplementation 1 | Faecal samples will be used for next-generation sequencing and analysed for changes in bacterial species levels | 3 weeks | |
Secondary | Changes in microbiota diversity 3 weeks after study supplementation 2 | Faecal samples will be used for next-generation sequencing and analysed for changes in microbiota diversity | 3 weeks | |
Secondary | Changes in bacterial species 3 weeks after study supplementation 2 | Faecal samples will be used for next-generation sequencing and analysed for changes in bacterial species levels | 3 weeks | |
Secondary | Changes in microbiota diversity 3 weeks after study supplementation 3 | Faecal samples will be used for next-generation sequencing and analysed for changes in microbiota diversity | 3 weeks | |
Secondary | Changes in bacterial species 3 weeks after study supplementation 3 | Faecal samples will be used for next-generation sequencing and analysed for changes in bacterial species levels | 3 weeks | |
Secondary | Changes in microbiota diversity - Washout (1 week after ending supplementation 1, i.e. 4 weeks after baseline) | Faecal samples will be used for next-generation sequencing and analysed for changes in microbiota diversity from 1 weeks washout, after ending study supplementation 1 (4 weeks after baseline) | 4 weeks | |
Secondary | Changes in bacterial species - Washout (1 week after ending study supplementation 1, i.e. 4 weeks after baseline) | Faecal samples will be used for next-generation sequencing and analysed for changes in bacterial species from 1 weeks washout, after ending study supplementation 1 (4 weeks after baseline) | 4 weeks | |
Secondary | Changes in microbiota diversity - Washout (1 week after ending study supplementation 2, i.e. 4 weeks after baseline) | Faecal samples will be used for next-generation sequencing and analysed for changes in microbiota diversity from 1 weeks washout, after ending study supplementation 2 (4 weeks after baseline) | 4 weeks | |
Secondary | Changes in bacterial species - Washout (1 week after ending study supplementation 2, i.e. 4 weeks after baseline) | Faecal samples will be used for next-generation sequencing and analysed for changes in bacterial species from 1 weeks washout, after ending study supplementation 2 (4 weeks after baseline). | 4 weeks | |
Secondary | Changes in microbiota diversity - Washout (1 week after ending study supplementation 3, i.e. 4 weeks after baseline) | Faecal samples will be used for next-generation sequencing and analysed for changes in microbiota diversity from 1 weeks washout, after ending study supplementation 3 (4 weeks after baseline) | 4 weeks | |
Secondary | Changes in bacterial species - Washout (1 week after ending study supplementation 3, i.e. 4 weeks after baseline) | Faecal samples will be used for next-generation sequencing and analysed for changes in bacterial species from 1 weeks washout, after ending study supplementation 3 (4 weeks after baseline) | 4 weeks | |
Secondary | Changes in gastrointestinal symptom questionnaire scores | The Gastrointestinal Symptoms Rating Scale (GSRS) evaluates gastrointestinal (GI) symptoms based on the 5 domains diarrhoea, constipation, reflux, indigestion and abdominal pain. The symptoms are assessed with 15 items, ranging in scores 1 to 7 depending on their severity. A score of 1 represents "no problems" and score 7 represents "severe problems". The severity of symptoms may be defined as no problems (1 point), mild (1-2 points), moderate (2-4 points), and severe (4-7 points). The scores for each domain was calculated as the mean score of each corresponding item while the mean total GSRS score reflects the general severity of GI symptoms. | up to 13 weeks | |
Secondary | Changes in hospital and anxiety depression scores | The Hospital Anxiety and Depression Scale (HADS) was used to evaluate the psychological distress of study participants.This questionnaire consists of 14 items subdivided in two subscales for the assessment of anxiety or depression. The total score is used as a measure of general psychological distress. The minimum score is 0 and the maximum score is 21. A score > 8 on respective subscales indicates a significant level of anxiety or depression. | up to 13 weeks | |
Secondary | Changes in perceived stress scale scores | The perceived stress scale (PSS) consists of 10 items, including a number of direct questions about current levels of experienced stress. The respondent answers how often a certain emotion has been present during the past month. PSS scores are obtained by reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1 & 4 = 0) to the four positively stated items (items 4, 5, 7, & 8) and then summing across all scale items. Each item is rated on a 5-point scale ranging from never (0) to almost always (4). The questions in this scale ask about the responders feelings and thoughts during the last month. In each case the questionnaire requires the respondent to indicate by circling how often they felt or thought a certain way. | Up to 13 weeks | |
Secondary | Changes in quality of life questionnaire scores | The EuroQol 5D-5L (EQ-5D-5L) tool consists of two parts; 5Q-5D, which includes 5 items related to wellbeing and function (mobility, self-care, usual activities, pain/discomfort and anxiety/ depression) and the visual analogue scale, 5Q-5D-VAS, ranging from 0 to 100. | Up to 13 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05531396 -
Agility Training on Physical Performance, Cognitive Function and Brain Activities in Elderly
|
N/A | |
Completed |
NCT03580447 -
The Effect of Citrus Extract on Oxidative Stress
|
N/A | |
Recruiting |
NCT04096547 -
Rivaroxaban in Elderly NVAF Patients With or Without Renal Impairment
|
||
Completed |
NCT03339791 -
Sleeve Versus Bypass in Older Patients: a Randomized Controlled Trial
|
N/A | |
Completed |
NCT03566719 -
Effect of an Exercise Program on Risk of Fall in a Community Dwelling Older Adults
|
N/A | |
Completed |
NCT02138968 -
Clinical and Economic Assessment of a Pre-frail Screening Program
|
N/A | |
Completed |
NCT01368029 -
Safety of Lactobacillus Rhamnosus GG Vs. Placebo in Elderly Subjects Receiving Trivalent Inactivated Influenza Vaccine
|
Phase 1 | |
Not yet recruiting |
NCT01182961 -
The Use of Virtual Reality for the Gait Training of Elderly Fallers
|
N/A | |
Completed |
NCT01899586 -
Mechanisms and Functional Outcomes of Exercise Progression Models in the Elderly
|
N/A | |
Completed |
NCT00961012 -
The Big Squeeze (Lessening the Big Squeeze: The Effect of the Trunk Release on Interface Pressures of Individuals Seated in a High Fowler's Positions)
|
N/A | |
Completed |
NCT00748683 -
Development of an Integrated Health Care Environment for Elderly With RFID Technology
|
Phase 0 | |
Completed |
NCT00533065 -
Effects of Donepezil on Deficits Associated With Age-Related Decrease of Growth Hormone
|
N/A | |
Completed |
NCT00798668 -
The Body's Response to Food Intake in Trained, Older Adults
|
N/A | |
Completed |
NCT00324701 -
Telepsychology-Service Delivery for Depressed Elderly Veterans
|
N/A | |
Completed |
NCT00217113 -
An Intervention to Preserve Functional Status and Independence Among Community Dwelling Elderly
|
N/A | |
Completed |
NCT03666793 -
Comprehensive Management of Drug Prescriptions Throughout the Elderly Person's Hospital Care
|
N/A | |
Recruiting |
NCT06030804 -
Perioperative Dexmedetomidine and Long-term Survival After Cancer Surgery
|
N/A | |
Recruiting |
NCT05014750 -
Frailty of Elderly With Valvular Heart Disease and the Short Term Adverse Events
|
||
Completed |
NCT05021432 -
Virtual Reality And Task Oriented Circuit Training Among Elderly Population
|
N/A | |
Active, not recruiting |
NCT04132492 -
AGNES - Aging Nephropathy Study, a Prospective Observational Cohort of Chronic Kidney Disease in Elderly Patients
|